Tecnotree Recognized as Representative Vendor in Gartner Market Guide for CSP Customer Management and Experience Solutions
13.4.2023 13:46:00 EEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for 5G, IOT, and cloud-native technology, announced that it has been named as a representative vendor in the 2022 Gartner Market Guide for CSP Customer Management and Experience Solutions.
The Gartner report is authored by analysts Juha Korhonen, Amresh Nandan, Chris Meering, and Susan Welsh de Grimaldo. It focuses on two major components of Customer Management and Experience (CM&X) solutions, which benefit CSPs immensely. The Gartner market guide enables CSPs to understand market trends & sourcing strategies and keep up with the evolving CM&X solutions. It helps them transform themselves with advancing digital technologies, which further empowers them to manage different aspects of BSS (Business Support Systems), such as customers, services, products, and partners.
Tecnotree has been featured in Gartner for its complete range of CM&X solutions, which includes CRM solutions, self-care apps, product catalogue, customer management, customer journey orchestration, partner management, loyalty programs, Diwa Fintech platform, and for its multi-experience B2B2X ecosystem marketplace platform called Tecnotree Moments, which uses Azure and AWS cloud infrastructure with multitenant capabilities. The Surge, low/no-code platform provides intelligence-enabled customer experience and business orchestration capabilities that can be coupled with moments marketplace capabilities and core digital BSS functionality, that can drive IoT and 5G monetization and automation utilizing mutli-cloud technologies.
Tecnotree solutions assist customers on a BSS transformation journey from being a traditional Communications Services Provider (CSP) to a Digital Services Provider (DSP). With over 44 TM Forum Open APIs deployed for customer management, product and order management, partner management, rating & charging, billing and ecosystem management, Tecnotree helps in providing a complete Digital transformation as well as specific transformation related to customer experience and management. Tecnotree’s cloud-native, AI/ML enabled, and 5G-ready customer experience solutions include cutting-edge digital products. The Gartner report mentions that Tecnotree has implemented several of the TM Forum APIs for CM&X and is among the leading vendors in TM Forum Open APIs certification. The report further recognises the platform that employs a micro-services-based architecture with a unified product catalogue that facilitates customer onboarding, allows converged billing, launches multi-experience bundled offerings, and provides a 360-degree customer view through its patented “profile of one” technology.
‘We are pleased to be recognized in Gartner’s prestigious market guide for our CSP customer management and experience solutions for 2023 again in addition to the recognition that we already received for Revenue Management & Monetization in Q4 of 2022. Our AI-driven CSP solutions meet the rapidly evolving business needs and create 5G revenue opportunities for CSPs, enabling them to provide greater services across various functions. We offer our valued customers increased convenience and unlimited access to world-class products and solutions.’ said Padma Ravichander, CEO-Tecnotree.
She commented further, ‘Our consistent year-on-year inclusion in the Gartner market guide validates our position as being customer-focused in creating digital experiences and revolutionizing enterprise experience through ecosystem partnerships for new-age digital services in a consistent manner.’
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
Gartner Disclaimer
Gartner does not endorse any vendor, product, or service depicted in our research publications and does not advise technology users to select only those vendors with the highest ratings or other designations. Gartner’s research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005460/en/
Contact information
Padma Ravichander, Tecnotree CEO
Email: marketing@tecnotree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
